209 related articles for article (PubMed ID: 34157171)
1. Decreased Annexin A1 expression enhances sensitivity to docetaxel, cisplatin and 5-fluorouracil combination induction chemotherapy in oral squamous cell carcinoma.
Sun W; Zhao T; Aladelusi TO; Ju W; Zhang Z; Zhong L; Zhu D
J Oral Pathol Med; 2021 Sep; 50(8):795-802. PubMed ID: 34157171
[TBL] [Abstract][Full Text] [Related]
2. Low Annexin A1 expression predicts benefit from induction chemotherapy in oral cancer patients with moderate or poor pathologic differentiation grade.
Zhu DW; Liu Y; Yang X; Yang CZ; Ma J; Yang X; Qiao JK; Wang LZ; Li J; Zhang CP; Zhang ZY; Zhong LP
BMC Cancer; 2013 Jun; 13():301. PubMed ID: 23786757
[TBL] [Abstract][Full Text] [Related]
3. GDF15 is a potential predictive biomarker for TPF induction chemotherapy and promotes tumorigenesis and progression in oral squamous cell carcinoma.
Yang CZ; Ma J; Zhu DW; Liu Y; Montgomery B; Wang LZ; Li J; Zhang ZY; Zhang CP; Zhong LP
Ann Oncol; 2014 Jun; 25(6):1215-22. PubMed ID: 24669014
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel, cisplatin and 5-FU compared with docetaxel, cisplatin and cetuximab as induction chemotherapy in advanced squamous cell carcinoma of the head and neck: Results of a randomised phase II AGMT trial.
Keil F; Hartl M; Altorjai G; Berghold A; Riedl R; Pecherstorfer M; Mayrbäurl B; De Vries A; Schuster J; Hackl J; Füreder T; Melchardt T; Burian M; Greil R
Eur J Cancer; 2021 Jul; 151():201-210. PubMed ID: 34022697
[TBL] [Abstract][Full Text] [Related]
5. A multicenter randomized phase II trial of hyperthermia combined with TPF induction chemotherapy compared with TPF induction chemotherapy in locally advanced resectable oral squamous cell carcinoma.
Ren G; Ju H; Wu Y; Song H; Ma X; Ge M; Qiu W; Chen Y; He Y; Zhuang Q; Meng J; Guo W
Int J Hyperthermia; 2021; 38(1):939-947. PubMed ID: 34134574
[TBL] [Abstract][Full Text] [Related]
6. Stathmin guides personalized therapy in oral squamous cell carcinoma.
Ju WT; Ma HL; Zhao TC; Liang SY; Zhu DW; Wang LZ; Li J; Zhang ZY; Zhou G; Zhong LP
Cancer Sci; 2020 Apr; 111(4):1303-1313. PubMed ID: 31994271
[TBL] [Abstract][Full Text] [Related]
7. The baseline oral microbiota predicts the response of locally advanced oral squamous cell carcinoma patients to induction chemotherapy: A prospective longitudinal study.
Rui M; Zhang X; Huang J; Wei D; Li Z; Shao Z; Ju H; Ren G
Radiother Oncol; 2021 Nov; 164():83-91. PubMed ID: 34571091
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma.
Zhong LP; Zhang CP; Ren GX; Guo W; William WN; Sun J; Zhu HG; Tu WY; Li J; Cai YL; Wang LZ; Fan XD; Wang ZH; Hu YJ; Ji T; Yang WJ; Ye WM; Li J; He Y; Wang YA; Xu LQ; Wang BS; Kies MS; Lee JJ; Myers JN; Zhang ZY
J Clin Oncol; 2013 Feb; 31(6):744-51. PubMed ID: 23129742
[TBL] [Abstract][Full Text] [Related]
9. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Lorch JH; Goloubeva O; Haddad RI; Cullen K; Sarlis N; Tishler R; Tan M; Fasciano J; Sammartino DE; Posner MR;
Lancet Oncol; 2011 Feb; 12(2):153-9. PubMed ID: 21233014
[TBL] [Abstract][Full Text] [Related]
10. Long-term results of a randomized phase III trial of TPF induction chemotherapy followed by surgery and radiation in locally advanced oral squamous cell carcinoma.
Zhong LP; Zhang CP; Ren GX; Guo W; William WN; Hong CS; Sun J; Zhu HG; Tu WY; Li J; Cai YL; Yin QM; Wang LZ; Wang ZH; Hu YJ; Ji T; Yang WJ; Ye WM; Li J; He Y; Wang YA; Xu LQ; Zhuang Z; Lee JJ; Myers JN; Zhang ZY
Oncotarget; 2015 Jul; 6(21):18707-14. PubMed ID: 26124084
[TBL] [Abstract][Full Text] [Related]
11. Significance of mammalian target of rapamycin in patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil.
Li SH; Lin WC; Huang TL; Chen CH; Chiu TJ; Fang FM; Huang WT; Hsu CM; Luo SD; Lai CC; Su YY; Chuang HC; Chien CY
Head Neck; 2016 Apr; 38 Suppl 1():E844-52. PubMed ID: 25917382
[TBL] [Abstract][Full Text] [Related]
12. MiR-92b as a marker for TPF induced chemotherapy response prediction and prognosis evaluation in with advanced oral squamous cell carcinoma patients.
Wen J; Xu H; Liu R; Chen Q; Dai Y; Xu Y
Cell Mol Biol (Noisy-le-grand); 2020 Jun; 66(3):24-31. PubMed ID: 32538743
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial.
Hitt R; Iglesias L; López-Pousa A; Berrocal-Jaime A; Grau JJ; García-Girón C; Martínez-Trufero J; Guix M; Lambea-Sorrosal J; Del Barco-Morillo E; León-Vintró X; Cunquero-Tomas AJ; Baste N; Ocaña A; Cruz-Hernández JJ;
Clin Transl Oncol; 2021 Apr; 23(4):764-772. PubMed ID: 32797376
[TBL] [Abstract][Full Text] [Related]
14. Normal BMI predicts the survival benefits of inductive docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced oral squamous cell carcinoma.
Zhao TC; Liang SY; Ju WT; Liu Y; Tan YR; Zhu DW; Zhang CP; Zhang ZY; Zhong LP
Clin Nutr; 2020 Sep; 39(9):2751-2758. PubMed ID: 31839432
[TBL] [Abstract][Full Text] [Related]
15. STAT3- and GSK3β-mediated Mcl-1 regulation modulates TPF resistance in oral squamous cell carcinoma.
Maji S; Shriwas O; Samal SK; Priyadarshini M; Rath R; Panda S; Das Majumdar SK; Muduly DK; Dash R
Carcinogenesis; 2019 Mar; 40(1):173-183. PubMed ID: 30395230
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil combined with cisplatin concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: a matched pair analysis.
Teo M; Karakaya E; Young CA; Dyker KE; Coyle C; Sen M; Prestwich RJ
Clin Oncol (R Coll Radiol); 2013 Nov; 25(11):647-53. PubMed ID: 23948462
[TBL] [Abstract][Full Text] [Related]
17. Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials.
Budach W; Bölke E; Kammers K; Gerber PA; Orth K; Gripp S; Matuschek C
Radiother Oncol; 2016 Feb; 118(2):238-43. PubMed ID: 26589131
[TBL] [Abstract][Full Text] [Related]
18. Phase 3 RCT comparing docetaxel-platinum with docetaxel-platinum-5FU as neoadjuvant chemotherapy in borderline resectable oral cancer.
Noronha V; Patil V; Chaturvedi P; Mathrudev V; Menon N; Bhattacharjee A; Singh A; Peelay Z; Chakraborty S; Jadhav M; Alone M; Bhagyavant P; Kolkur M; Srinivas S; Das S; Roy S; Mandal T; Dsouza H; Saha S; Rai R; Srikanth A; Shah D; Khan A; Muthuluri H; Kumar A; Agarwal A; Rajpurohit A; Goli VB; Sekar A; Mantri A; Kanteti APK; Majumdar S; Khaddar S; Shenoy R; Elamarthi P; Rathnasamy N; Kashyap L; Abraham G; Booma N; Simha V; Chaukar D; Pai P; Nair S; Laskar S; Nawale K; Naidu P; Salian S; Shelar P; Raulo R; Dhumal SB; Prabhash K
Eur J Cancer; 2024 Mar; 200():113560. PubMed ID: 38306841
[TBL] [Abstract][Full Text] [Related]
19. Cyclin D1 overexpression enhances chemosensitivity to TPF chemotherapeutic agents via the caspase-3 pathway in oral cancer.
Hu YJ; Sun WW; Zhao TC; Liu Y; Zhu DW; Wang LZ; Li J; Zhang CP; Zhang ZY; Zhong LP
Oncol Lett; 2020 Nov; 20(5):154. PubMed ID: 32934722
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of dose-modified docetaxel plus cisplatin-based induction chemotherapy in Asian patients with locally advanced head and neck cancer.
Huang CE; Lu CH; Chen PT; Chan CH; Chen WC; Wang WH; Wu JY; Kuan FC; Lee KD; Chen CC
J Clin Pharm Ther; 2012 Jun; 37(3):342-7. PubMed ID: 21950487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
